MRVI vs. ARWR, TWST, VCEL, KNSA, NAMS, DNLI, RXRX, BLTE, CGON, and INDV
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Vericel (VCEL), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Recursion Pharmaceuticals (RXRX), Belite Bio (BLTE), CG Oncology (CGON), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.
Maravai LifeSciences vs. Its Competitors
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.
62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 2.1% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Arrowhead Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.
Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -67.14%. Maravai LifeSciences' return on equity of -12.91% beat Arrowhead Pharmaceuticals' return on equity.
Maravai LifeSciences has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Maravai LifeSciences had 3 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 5 mentions for Maravai LifeSciences and 2 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.14 beat Maravai LifeSciences' score of 0.43 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.
Arrowhead Pharmaceuticals currently has a consensus target price of $43.71, indicating a potential upside of 158.66%. Maravai LifeSciences has a consensus target price of $6.64, indicating a potential upside of 150.52%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Maravai LifeSciences.
Summary
Arrowhead Pharmaceuticals beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:MRVI) was last updated on 7/3/2025 by MarketBeat.com Staff
Free MRVI Stock Alerts